ライフサイエンスコーパス: obesity-related

1 l fibroblast cross-talk, was enhanced by the obesity-related adipokine leptin.

2 es have addressed causes and consequences of obesity-related adipose tissue hypertrophy and hyperplas

3 o association was observed for either of the obesity-related anthropometric measures after adjustment

4 Central obesity-related anthropometric parameters were measured

5 is compound shows potential in counteracting obesity-related anxiety.

6 Rationale: Obesity-related asthma disproportionately affects minori

7 Pediatric obesity-related asthma is more severe and less responsiv

8 inical evidence supports the existence of an obesity-related asthma phenotype.

9 ; P = .003) and appear to mediate overweight/obesity-related asthma symptoms.

10 fying them as a novel therapeutic target for obesity-related asthma, a disease that is suboptimally r

11 on deficits found in patients with pediatric obesity-related asthma.

12 ary function deficits found in patients with obesity-related asthma.

13 duce their sedentary time to prevent central obesity-related asthma.

14 loci that were independently associated with obesity-related asthma.Measurements and Main Results: Ob

15 fat cell lipid accumulation; it demonstrates obesity-related attenuated autophagy in adipocytes, and

16 omes in the elderly, the biological bases of obesity-related behaviors during aging are poorly unders

17 nd to reduce metabolic endotoxemia and other obesity-related biochemical abnormalities.

18 may impact study outcome when screening for obesity-related biomarkers and we identify several marke

19 r repletion supports weight loss and changes obesity-related biomarkers is unknown.

20 owever, there are little data on the role of obesity-related biomarkers on liver cancer risk.

21 Corresponding obesity-related biomarkers were measured in 10 overweigh

22 Thus, obesity-related brain adaptations to glucose and fructos

23 9a signaling regulates CSC plasticity during obesity-related breast cancer progression, suggesting a

24 Total circulating BCAAs were unrelated to obesity-related cancer incidence although an association

25 ation of macrophages-key cellular players in obesity-related cancer progression.

26 The risk of developing an obesity-related cancer seems to be increasing in a stepw

27 ation was observed for leucine with incident obesity-related cancer.

28 gested a modest association for leucine with obesity-related cancers (1.04 [1.00-1.08]), and no assoc

29 dered the 20 most common cancer types and 12 obesity-related cancers (30 cancer types in total).

30 icantly associated with the incidence of all obesity-related cancers (hazard ratio [HR] per 10-y incr

31 idence significantly increased for six of 12 obesity-related cancers (multiple myeloma, colorectal, u

32 However, BCAAs were not associated with obesity-related cancers (multivariable HR per SD = 1.01

33 m(2) was associated with 23% greater risk of obesity-related cancers (n = 2751 events; multivariable

34 esity, cardiovascular disease, hypertension, obesity-related cancers, and dental caries.

35 The endpoint was a composite of obesity-related cancers, defined per the International A

36 lating BCAAs may be associated with incident obesity-related cancers.

37 the USA for 30 common cancers, including 12 obesity-related cancers.

38 These findings may shed light onto obesity-related cardiac remodeling and heart failure.

39 se tissue dysfunction play a central role in obesity-related cardiometabolic complications.

40 Insulin resistance is a key mediator of obesity-related cardiometabolic disease, yet the mechani

41 abdominal) adipose tissue is associated with obesity-related cardiometabolic diseases, whereas lower-

42 trategy for weight loss and the treatment of obesity-related cardiometabolic diseases.

43 associations with body mass index (BMI) and obesity-related cardiometabolic diseases.

44 y of overall strength capacity-may attenuate obesity-related cardiometabolic risk.

45 , we could not separate the contributions of obesity-related cardiovascular risk factors, such as dia

46 and MAM formation in mouse liver cells, and obesity-related cellular changes that are closely associ

47 rmed M-insulin resistant, which accounts for obesity-related changes in macrophage responses and a st

48 2008, we documented 8,755 incident cases of obesity-related chronic diseases (type 2 diabetes mellit

49 Weight loss improves almost all obesity-related co-morbidities and metabolic markers, re

50 iatric surgery, weight, body mass index, and obesity-related co-morbidities.

51 ric bypass resulted in large improvements in obesity-related comorbid disease and sustained weight lo

52 mportantly, a highly significant decrease in obesity-related comorbid disease persisted at 10 years o

53 n for long-term weight loss and treatment of obesity-related comorbid disease.

54 ty and increases time taken to conceive, and obesity-related comorbidities (such as type 2 diabetes a

55 s, all of which can result in a reduction in obesity-related comorbidities and improvements in qualit

56 reasing, but data on its long-term effect on obesity-related comorbidities are scarce.

57 disease, has nearly doubled since 1980, and obesity-related comorbidities have become a major threat

58 on in obese AT, lending further insight into obesity-related comorbidities in humans.

59 weight loss and accompanying improvements in obesity-related comorbidities produced by intensive life

60 ve contribution of cardiometabolic and other obesity-related comorbidities to such effects remains un

61 im of this study was to compare weight loss, obesity-related comorbidities, and biochemical outcomes

62 eeve gastrectomy (SG) regarding weight loss, obesity-related comorbidities, and complications.

63 ect higher rates of diabetes mellitus, other obesity-related comorbidities, and mortality.

64 Excess weight loss, obesity-related comorbidities, and partial and complete

65 y endpoints included the surgery's impact on obesity-related comorbidities, quality of life, and comp

66 cient weight loss and a major improvement in obesity-related comorbidities, with mostly no correlatio

67 ly quantify the indirect effects mediated by obesity-related comorbidities.

68 nd risk for death, even after adjustment for obesity-related comorbidities.

69 ically relevant benefits for the majority of obesity-related comorbidities.

70 ions are currently used to treat obesity and obesity-related comorbidities.

71 of 40 or higher or 35 or higher with serious obesity-related comorbidities.

72 /m2 or greater in the presence of at least 1 obesity-related comorbidity.

73 ay of multiple organs in the pathogenesis of obesity-related complications such as NAFLD and provides

74 ays a significant role in the development of obesity-related complications, but the molecular events

75 herapies due to dose limiting toxicities and obesity-related complications, highlighting the need to

76 portant role for gastric tissue in promoting obesity-related complications.

77 t an effective strategy to treat obesity and obesity-related complications.

78 nonalcoholic fatty liver disease (NAFLD), an obesity-related condition that recently has become the m

79 index of 40 to 45 or 35 to 40 and 1 or more obesity-related condition was conducted at 10 sites in t

80 he use of MBS as a treatment for obesity and obesity-related conditions and, based on recent evidence

81 Obesity-related conditions including heart disease, stro

82 r disease (NAFLD) and heart failure (HF) are obesity-related conditions with high cardiovascular mort

83 Vitamin D deficiency is associated with obesity-related conditions, but the role of early life v

84 ffects mediated by cardiometabolic and other obesity-related conditions, suggesting the possible role

85 with diet but contributes to improvements in obesity-related conditions.

86 Given the improvement of established obesity-related CVD risk factors after weight loss, it i

87 Growing evidence indicates that resistin-an obesity-related cytokine-is upregulated in breast cancer

88 ted traits in Mexican American (MA) children.Obesity-related data were obtained from 670 nondiabetic

89 aged or older men with either age-related or obesity-related decline in serum testosterone levels has

90 The prevalence of obesity-related diabetes is increasing worldwide.

91 sulin to control glucose homeostasis, but in obesity-related diabetes, there is a presumed deficit in

92 ing surgical procedures to treat obesity and obesity-related disease are increasing.

93 ng-term mortality and incidence of new-onset obesity-related disease at a national level.

94 ng-term all-cause mortality and incidence of obesity-related disease in patients with obesity for the

95 verse the global acceleration of obesity and obesity-related disease OEA is a promising candidate; ho

96 studies of the gut microbiome and abdominal obesity-related disease outcomes should account for sex-

97 h lipid overloading, thereby contributing to obesity-related disease.

98 udied sirtuin, SIRT1, counteracts aging- and obesity-related diseases by deacetylating many proteins,

99 tive risk of long-term mortality or incident obesity-related diseases for patients who have undergone

100 The search for biomarkers associated with obesity-related diseases is ongoing, but it is not clear

101 ic cellular and molecular mechanisms in most obesity-related diseases remains an important challenge.

102 ) is commonly recommended for improvement of obesity-related diseases such as NAFLD.

103 h plays a key role in the pathophysiology of obesity-related diseases such as type 2 diabetes and non

104 s all-cause mortality and the development of obesity-related diseases such as type 2 diabetes mellitu

105 obesity as physicians caring for people with obesity-related diseases, in addition to their expertise

106 c potential of BAT to counteract obesity and obesity-related diseases, including insulin resistance.

107 (SIRT1) deacetylase delays and improves many obesity-related diseases, including nonalcoholic fatty l

108 WATi) has been linked to the pathogenesis of obesity-related diseases, including type 2 diabetes, car

109 g new therapeutic approaches for obesity and obesity-related diseases, including type 2 diabetes.

110 are an important contributor to obesity and obesity-related diseases, including type 2 diabetes.

111 ttractive therapeutic target for obesity and obesity-related diseases, including type 2 diabetes.

112 tion of AdipoR agonists for the treatment of obesity-related diseases, such as type 2 diabetes.

113 ic approach for treatment of NAFLD and other obesity-related diseases.

114 e Australian population, taking into account obesity-related diseases.

115 hich may be implicated in the progression of obesity-related diseases.

116 ed molecular features that may contribute to obesity-related diseases.

117 n, providing a potential target for treating obesity-related diseases.

118 y metabolism, has potential for treatment of obesity-related diseases.

119 lular metabolism are unclear but relevant to obesity-related diseases.

120 Obesity and obesity-related disorders are a global epidemic affectin

121 ncidence was not associated with obesity and obesity-related disorders including liver steatosis, glu

122 d a significant economic investment to treat obesity-related disorders such as type 2 diabetes, cardi

123 hospholipid metabolism in the progression of obesity-related disorders.

124 ases, such as inflammatory bowel disease and obesity-related disorders.

125 Weight loss improves obesity-related disorders.

126 related sleep issues are linked to insomnia, obesity-related disparities center on sleep-related brea

127 Obesity-related dysregulation of leptin signaling (e.g.,

128 im was to evaluate dietary, reproductive and obesity-related factors and GBD in multiethnic populatio

129 Overall, dietary, reproductive and obesity-related factors are strong risk factors for GBD

130 Several obesity-related factors have been associated with renal

131 review will be the impact of these systemic obesity-related factors on cancer biology, incidence, an

132 The fat mass and obesity-related (FTO) single-nucleotide polymorphism (SN

133 ilities for preventing and controlling human obesity-related gastrointestinal cancers that often exhi

134 T expression of CNV12, which overlap with an obesity related gene Netrin-1 (Ntn1), were consistent wi

135 association between DNA methylation level in obesity-related genes and body mass index (BMI) percenti

136 Discovering the mechanisms through which obesity-related genes influence weight would help pinpoi

137 r data would suggest that DNA methylation in obesity-related genes may relate to obesity risk in adol

138 Obesity-related genes were significantly enriched among

139 permutation tests were used to determine if obesity-related genes were significantly enriched among

140 ile with p < 0.05, 28 were identified within obesity-related genes.

141 raits mediate the associations between known obesity-related genetic variants and adiposity.

142 lymorphisms identified in a meta-analysis of obesity-related genome-wide association studies.

143 lated by high glucose and/or fatty acids, in obesity-related glomerulopathy (ORG) and diabetic nephro

144 hritis (MPGN), diabetic nephropathy (DN) and obesity-related glomerulopathy (ORG), while the frequenc

145 iet providing 42% of energy as fat developed obesity-related glucose intolerance by 6 months.

146 uman pregnancy might contribute to long-term obesity-related health concerns in offspring.

147 icals that may contribute to diabetes and to obesity-related health outcomes by summarizing relevant

148 o better understand the influence of diet on obesity-related health outcomes, efforts to reduce dieta

149 ass index [BMI] z score, >/=3.0 or >2.3 with obesity-related health problems).

150 al therapeutic target to improve symptoms in obesity-related heart disease, and a fascinating modifia

151 cies in the liver, which plays a key role in obesity-related hepatic insulin resistance.

152 Obesity-related HFpEF is a genuine form of cardiac failu

153 oints included short-term weight loss, serum obesity-related hormone levels, hunger and satiety asses

154 (PVAT) and has been implicated in resultant obesity-related hypertension and impaired glucose intole

155 It is proposed that obesity-related hypertension has a neurogenic component

156 Obesity-related hypertension is a common disorder, and a

157 nt (Mc4rKO) mice are severely obese but lack obesity-related hypertension; they also show a reduced p

158 ce of obesity on cognition in the absence of obesity-related illnesses.

159 he impact of 12 weeks of aerobic exercise on obesity-related impairments in insulin sensitivity and m

160 33, and gammadelta T cell deficiency reduced obesity-related increases in the response to ozone, incl

161 vestigate the role of Th2/M2 polarization in obesity-related inflammation and insulin resistance, we

162 eficial role of vitamin D supplementation on obesity-related inflammation.

163 forging collaboration with groups working on obesity-related initiatives both within and outside of t

164 Obesity-related insulin resistance (IR) may develop in m

165 to failed insulin secretory compensation to obesity-related insulin resistance and dysmetabolism.

166 y have potential therapeutic implications in obesity-related insulin resistance and other metabolic c

167 y missing links and potential mechanisms for obesity-related insulin resistance and type 2 diabetes t

168 Obesity-related insulin resistance is associated with an

169 ose tissue contributes to the development of obesity-related insulin resistance through increased rel

170 tathionine gamma-lyase deficiency aggravates obesity-related insulin resistance via FoxO1-dependent h

171 m is emerging as an important contributor to obesity-related insulin resistance, but the role of inte

172 ofile is highlighted in its association with obesity-related insulin resistance, type 2 diabetes mell

173 tion has on increasing beta-cell mass during obesity-related insulin resistance.

174 AT) as a key contributor to inflammation and obesity-related insulin resistance.

175 thought to contribute to the development of obesity-related insulin resistance.

176 a promising therapeutic potential target for obesity-related insulin resistance.

177 eptibility to type 1 diabetes results in non-obesity-related, insulin-dependent diabetes, which prese

178 5 have renoprotective roles in diabetes- and obesity-related kidney disease.

179 lyase is an epigenetic regulator to promote obesity-related kidney injury.

180 kers to predict progression and prognosis of obesity related liver diseases.

181 myeloid leukemia, debilitating fibroses, and obesity-related liver dysfunction.

182 es; however, the role of B7 costimulation in obesity-related liver inflammation is unknown.

183 netic inactivation of B7.1/B7.2 deteriorates obesity-related liver steatosis and metabolic dysregulat

184 at the effects of a polygenic risk score (90 obesity-related loci) on measured body mass index and wa

185 mmatory functions of each monocyte subset in obesity-related low-grade inflammation.

186 xE to complex traits is substantial for nine obesity-related measures (including leg impedance and tr

187 D2R function better than other commonly used obesity-related measures such as BMI.

188 CD1 represents a potential target to resolve obesity related metabolic diseases; SCD1 deficiency caus

189 ey disease (CKD) among obese persons without obesity-related metabolic abnormalities, called metaboli

190 ts with atypical depression characterized by obesity-related metabolic alterations.

191 complex in humans can be used as therapy for obesity-related metabolic defects.

192 ose tissue (AT) and liver, thereby mediating obesity-related metabolic deterioration.

193 st that beta3-AR agonists could also improve obesity-related metabolic disease by increasing brown ad

194 e to impaired adipogenic differentiation and obesity-related metabolic disease.

195 p a potentially novel therapeutic avenue for obesity-related metabolic disease.

196 9 may be an effective strategy for combating obesity-related metabolic disease.

197 association of visceral adipose tissue with obesity-related metabolic diseases, the distribution of

198 s endocrine-disrupting chemicals (EDCs) with obesity-related metabolic diseases.

199 to be a good candidate for the treatment of obesity-related metabolic diseases.

200 rebiotic agents to prevent gut dysbiosis and obesity-related metabolic disorders in obese individuals

201 mation (metaflammation) is characteristic of obesity-related metabolic disorders, associated with inc

202 ty acids have not been fully investigated in obesity-related metabolic disorders.

203 n sensitivity and has the potential to treat obesity-related metabolic disorders.

204 ntial therapeutic and diagnostic targets for obesity-related metabolic disorders.

205 ides novel insights into strategies to treat obesity-related metabolic disorders.

206 Nonalcoholic fatty liver is associated with obesity-related metabolic disturbances, but little is kn

207 w insights into mechanism(s) responsible for obesity-related metabolic dysfunction and disease.

208 lyphenols, cumulative effects in attenuating obesity-related metabolic dysfunction may require increa

209 gy, prevention, and treatment of obesity and obesity-related metabolic dysfunction, including type 2

210 erventions aimed at ameliorating obesity and obesity-related metabolic dysfunction.

211 ng with the activity of both kinases reduces obesity-related metabolic dysfunctions in mouse models a

212 ontributor in the development of obesity and obesity-related metabolic dysfunctions, amongst others.

213 may provide a novel therapeutic approach for obesity-related metabolic dysregulation and, especially,

214 tory state present in obesity contributes to obesity-related metabolic dysregulation, including nonal

215 2 (double knockout; DKO) revealed aggravated obesity-related metabolic dysregulation, reduced insulin

216 secondary outcomes were 12-month changes in obesity-related metabolic markers (blood pressure, low-

217 sociated with subsequent change in different obesity-related metabolic markers, but due to multiple-t

218 istory of major depressive disorder (MDD) on obesity-related metabolic responses to high-fat meals.

219 bolomic profiles associated with obesity and obesity-related metabolic traits.

220 eas CCR5 expression was positively linked to obesity-related metabolic traits.

221 g to weight), yielding relevant profiles (45 obesity-related metabolites) and discriminative fingerpr

222 of reward-related regions is associated with obesity-related metrics and early weight gain.

223 Exercise training reversed obesity-related mitochondrial derangements as evidenced

224 in studies on the role of gut microbiota in obesity-related mood disorders.

225 d in relation to all-cause mortality and the obesity-related morbidities cardiovascular disease, diab

226 Obesity-related morbidities could account for these find

227 reported role of FABP4 in the development of obesity-related morbidities, including insulin resistanc

228 loss control groups and in individuals with obesity-related morbidities.

229 to adverse cardiovascular outcomes or other obesity-related morbidity, such as type 2 diabetes.

230 Bariatric surgery reduces obesity-related mortality.

231 d to improve liver function in patients with obesity-related NAFLD.

232 the validation phase) were used to identify obesity related neutrophil activation markers and their

233 sted that ITCH deficiency protects mice from obesity-related nonalcoholic fatty liver disease.

234 igher odds of overweight, obesity, and other obesity-related outcomes [body mass index (BMI), BMI z s

235 However, there is marked heterogeneity in obesity-related outcomes among individuals.

236 : does early-life exposure to BPA affect the obesity-related outcomes body weight, fat (pad) weight,

237 icals of potential interest for diabetes- or obesity-related outcomes using high-throughput screening

238 studies of urinary biomarkers and obesity or obesity-related outcomes, alternative metrics such as ur

239 n studies of urinary analytes and obesity or obesity-related outcomes, controlling for creatinine cou

240 nery consumption and overweight, obesity, or obesity-related outcomes.

241 d to the beneficial action of fruits against obesity-related oxidative stress.

242 postulated to be a major contributor to many obesity-related pathologies.

243 Thus, adipose-resident ILC1s contribute to obesity-related pathology in response to dysregulated lo

244 in WAT and a potential target for mitigating obesity-related pathology.

245 gnals appear related to T2DM via glucose and obesity-related pathways acting before the collection of

246 ntial outcome approach was used to determine obesity-related periodontitis risk using the Australian

247 We hypothesized that specific obesity-related phenotypes are associated with distinct

248 eutic target for influencing health span and obesity-related phenotypes as well as tumor growth.

249 nic chemicals results in the transmission of obesity-related phenotypes through at least three genera

250 METHODS AND We evaluated the associations of obesity-related phenotypes, including central adiposity,

251 ble genetic influence and is associated with obesity-related phenotypes.

252 e tissue biology and have clinical impact in obesity-related phenotypes.

253 od epilepsy and examine associations between obesity-related pregnancy and neonatal complications and

254 The diagnosis of epilepsy as well as obesity-related pregnancy and neonatal complications wer

255 weight or obese mothers was not explained by obesity-related pregnancy or neonatal complications.

256 Obesity-related reduction in pulmonary function is a pos

257 Our results show that obesity-related risk allele carriers of FTO gene show do

258 Moreover, the obesity-related risk allele is associated with reduced m

259 Women self-reported body weight along with obesity-related risk factors on baseline and annual foll

260 These GPCs may be sensitive indicators of obesity-related risk for CVD outcomes in adults, and may

261 explanations for the apparent attenuation of obesity-related risks in older adults.

262 al role of B7 costimulation in the course of obesity-related sequelae, particularly NASH.

263 ygenic risk score (PRS) comprising 28 common obesity-related single-nucleotide polymorphisms identifi

264 To avoid the confounding effect of obesity-related steatosis, only 70 individuals who had c

265 may be a therapeutic strategy to ameliorate obesity-related steatosis.

266 rations in MAIT cells may be contributing to obesity-related sterile inflammation and insulin resista

267 Obesity-related structural and functional changes in the

268 Obesity-related sub-acute chronic inflammation has been

269 We hypothesized that obesity-related systemic inflammation and B-cell stress

270 ferent immune features: airway neutrophilia, obesity-related systemic inflammation, or in some cases,

271 e mechanisms of local immune disturbances in obesity-related T2D.

272 black tea (Camellia sinensis) theaflavins on obesity-related targets.

273 whether SNPs in WNT4 and WNT5A contribute to obesity related traits in Han Chinese population.

274 y 69 new genes significantly associated with obesity-related traits (BMI, lipids and height).

275 d a different degree of genetic overlap with obesity-related traits (body mass index [BMI] and levels

276 and examined their genetic relation with 10 obesity-related traits [body mass index (BMI), waist cir

277 and 60 DEGs were found to be associated with obesity-related traits and diseases, consolidating evide

278 66 (PDE3B), that substantially contribute to obesity-related traits and experimentally demonstrate th

279 evaluate the causal relationship between the obesity-related traits and meningioma risk, we consider

280 d advice provides extra benefits in reducing obesity-related traits compared with the benefits of con

281 Obesity and obesity-related traits have been reported in several epi

282 d colleagues show that regional variation of obesity-related traits in a Scottish population is influ

283 ences on serum carotenoid concentrations and obesity-related traits in Mexican American (MA) children

284 risk had a greater effect on a reduction of obesity-related traits in risk carriers than in nonrisk

285 ons between atypical depressive symptoms and obesity-related traits may arise from shared pathophysio

286 Using data on obesity-related traits of 11,000 Scottish individuals wi

287 tion analysis including 21 inversions and 25 obesity-related traits on a total of 408,898 Europeans a

288 analysis of genetic variants associated with obesity-related traits to assess the relationship with m

289 Interestingly, obesity-related traits were associated with distinct asp

290 relationship between mean adipocyte area and obesity-related traits, and identify genetic factors ass

291 ide polymorphisms (SNPs) possibly acting via obesity-related traits, hsCRP, based on 16 SNPs from gen

292 We considered 11 obesity-related traits, identified genetic instruments f

293 implicated loci have been reported for adult obesity-related traits, less is known about the genetics

294 dence of gene-smoking interaction (GxSMK) on obesity-related traits.

295 en investigating the genetic contribution to obesity-related traits.

296 tissues revealed strong candidate genes for obesity-related traits.

297 and in differential expression analysis with obesity-related traits.

298 Obesity-related type 2 diabetes (DM) is a major public h

299 d persist more than other complications, and obesity-related type 2 diabetes could have increasing ef

300 vent about 274,000-309,000 incident cases of obesity-related type 2 diabetes over the two decades aft